roxadustat

Phase 1Completed

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Anemia

Conditions

Anemia, Hemodialysis, Renal Impairment

Trial Timeline

Feb 15, 2010 → Jun 7, 2010

NCT ID

NCT01083888

About roxadustat

roxadustat is a phase 1 stage product being developed by Astellas Pharma for Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01083888. Target conditions include Anemia, Hemodialysis, Renal Impairment.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (12)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05970172	Phase 3	Recruiting	Jan 16, 2024	Oct 30, 2027	Chronic Kidney Disease
NCT04408820	Pre-clinical	Completed	Jun 1, 2020	Jun 23, 2025	Renal Anemia
NCT04076943	Phase 2	Completed	Aug 20, 2019	Apr 23, 2021	Chemotherapy Induced Anemia
NCT03960489	Phase 1	Completed	Jul 31, 2019	Oct 14, 2019	Healthy Adult Subjects
NCT02964936	Phase 3	Completed	Jan 11, 2017	Aug 15, 2018	Chronic Kidney Disease
NCT02965040	Phase 1	Completed	Dec 12, 2016	Dec 11, 2017	Normal Renal Function
NCT02780726	Phase 3	Completed	Jun 22, 2016	Aug 2, 2017	Peritoneal Dialysis Chronic Kidney Disease Patients With Anemia
NCT02780141	Phase 3	Completed	Jun 2, 2016	Dec 12, 2017	ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia
NCT02779764	Phase 3	Completed	May 16, 2016	Nov 28, 2017	Hemodialysis Patients With Renal Anemia
NCT01630889	Phase 2	Completed	May 18, 2012	Dec 12, 2019	Chronic Kidney Disease
NCT01244763	Phase 2	Completed	Oct 29, 2010	Jun 13, 2012	Chronic Kidney Disease
NCT01083888	Phase 1	Completed	Feb 15, 2010	Jun 7, 2010	Anemia

Competing Products

20 competing products in Anemia

See all competitors

Product	Company	Stage	Hype Score
Aranesp®	Amgen	Approved	84
KER-047	Keros Therapeutics	Phase 2	44
LY2787106	Eli Lilly	Phase 1	33
R744 + R744	Chugai Pharmaceutical	Phase 3	77
epoetin beta + placebo	Chugai Pharmaceutical	Phase 3	77
recombinant human erythropoietin + recombinant human erythropoietin placebo	Chugai Pharmaceutical	Phase 3	77
recombinant human erythropoietin + recombinant human erythropoietin	Chugai Pharmaceutical	Phase 3	77
darbepoetin alfa	Amgen	Phase 3	76
Prasugrel	Daiichi Sankyo	Phase 1	33
Prasugrel + Placebo	Daiichi Sankyo	Phase 2	52
roxadustat	Astellas Pharma	Phase 3	77
roxadustat	Astellas Pharma	Phase 3	77
Roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	77
Alefacept	Astellas Pharma	Phase 1	33
Roxadustat	Astellas Pharma	Phase 2	52
Roxadustat + Placebo	Astellas Pharma	Phase 3	77
Roxadustat	Astellas Pharma	Pre-clinical	23
Roxadustat + Epoetin Alfa	Astellas Pharma	Phase 3	77
roxadustat + Darbepoetin alfa	Astellas Pharma	Phase 3	77
roxadustat	Astellas Pharma	Phase 3	77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved